CASI Pharmaceuticals, Inc.
CASI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$39,258 | -$26,938 | -$40,257 | -$35,842 |
| Dep. & Amort. | $2,331 | $3,741 | $2,422 | $1,815 |
| Deferred Tax | $0 | $0 | $0 | -$5,202 |
| Stock-Based Comp. | $1,306 | $7,217 | $7,010 | $7,770 |
| Change in WC | $771 | -$7,818 | -$6,650 | -$3,218 |
| Other Non-Cash | $5,626 | $3,831 | $16,387 | $7,835 |
| Operating Cash Flow | -$29,224 | -$19,967 | -$21,088 | -$26,842 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$223 | -$204 | -$5,612 | -$15,500 |
| Net Acquisitions | -$1,370 | $0 | $138 | $10 |
| Inv. Purchases | -$1,407 | -$51,754 | -$7,425 | -$12,402 |
| Inv. Sales/Matur. | $13,761 | $44,322 | $37,622 | $172 |
| Other Inv. Act. | $483 | -$2,037 | $6,436 | $7,029 |
| Investing Cash Flow | $11,244 | -$9,673 | $31,159 | -$20,691 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | -$839 |
| Stock Issued | $15,000 | $0 | $0 | $32,500 |
| Stock Repurch. | $0 | -$278 | -$3,267 | $0 |
| Dividends Paid | -$718 | -$738 | $0 | $0 |
| Other Fin. Act. | $1,152 | $0 | $0 | -$2,019 |
| Financing Cash Flow | $15,434 | -$907 | -$3,267 | $29,642 |
| Forex Effect | -$1,069 | $518 | $1,604 | -$469 |
| Net Chg. in Cash | -$3,615 | -$30,029 | $8,408 | -$18,360 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $17,083 | $47,112 | $38,704 | $57,064 |
| End Cash | $13,468 | $17,083 | $47,112 | $38,704 |
| Free Cash Flow | -$29,464 | -$22,208 | -$26,700 | -$42,342 |